The primary datasets for this work are the ownership of the NCI-SEER (these are third party data i.e., data not owned or collected by the author). They can be accessed in the same manner as the authors through the SEER\*stat program (<https://seer.cancer.gov/seerstat/>).

1. Introduction {#sec005}
===============

Prostate cancer is the 2^nd^ most cancer among men and the 4^th^ most common cancer in both sexes.Approximately 1.1 million patients were diagnosed with prostate cancer in 2012 according to globocan\[[@pone.0188450.ref001]\]. Moreover, prostate cancer is the 5^th^ leading cause of mortality from cancer in men \[[@pone.0188450.ref002]\].

Principles of therapy of patients with prostate cancer have incorporated multiple domains; namely: patient domain (fitness, and co-morbidity) and tumor domain (stage and grade) \[[@pone.0188450.ref003]\]. Successive editions from the most common staging system for prostate cancer (the American Joint Committee on Cancer (AJCC)) system have been published reflecting progress in our understanding of prostate cancer biology and prognosis. The most recent edition (8^th^ edition) has been published in December 2016 and its implementation was delayed till January 2018 \[[@pone.0188450.ref004], [@pone.0188450.ref005]\]. Notable changes in the 8^th^ edition include: (1) pathologically organ-confined disease should be considered as pT2 and should not be classified based on extent or laterality. (2) Histologic grade should be expressed by grade grouping system. (3) T4N0M0 disease is stage IIIB rather than stage IV. (4) Introduction of newer sub-stages within the realm of stage II and stage III. Summary of the AJCC 8^th^ stage grouping for prostate cancer with comparison to previous staging systems is provided in [Table 1](#pone.0188450.t001){ref-type="table"} \[[@pone.0188450.ref006]\]\[[@pone.0188450.ref007]\]. It has to be noted that the first publication proposing the grade group approach to prostate cancer was from Hopkins group \[[@pone.0188450.ref008]\].

10.1371/journal.pone.0188450.t001

###### AJCC stage groupings 6^th^, 7^th^ and 8^th^ edition[\*](#t001fn001){ref-type="table-fn"}.

![](pone.0188450.t001){#pone.0188450.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Stage   AJCC 6^th^             AJCC 7^th^                                                              AJCC 8^th^
  ------- ---------------------- ----------------------------------------------------------------------- -------------------------------------------------
  I       T1a N0 G1              T1a-c N0 M0, PSA \< 10, Gleason ≤ 6T2a N0 M0, PSA \< 10, Gleason ≤ 6\   cT1a-T2a N0M0,PSA\<10, grade group 1
                                 T1-2a N0 M0, PSA X, Gleason X\                                          

  II      T1a G2-4, T1b-1c, T2   IIA: T1a-c N0 M0, PSA \< 20, Gleason 7\                                 IIA: cT1a-T2a, N0,M0,PSA 10--20, grade group 1\
                                 T1a-c N0 M0, PSA ≥ 10 \< 20, Gleason ≤ 6\                               IIA: cT2b-c, N0,M0, PSA\<20, grade group 1\
                                 T2a-b N0 M0, PSA \< 20, Gleason ≤7\                                     IIB: T1-2,N0,M0,PSA\<20, grade group 2\
                                 T2a N0 M0, PSA ≥ 10 \< 20, Gleason ≤ 6\                                 IIC: T1-2,N0,M0,PSA\<20,grade group 3,4
                                 T2b N0 M0, PSA X, Gleason X\                                            
                                 IIB: T2c N0 M0, Any PSA, Any Gleason\                                   
                                 T1-2 N0 M0, PSA ≥ 20, Any Gleason\                                      
                                 T1-2 N0 M0, Any PSA, Gleason ≥ 8                                        

  III     T3 N0                  T3a-b N0 M0, Any PSA, Any Gleason                                       IIIA: T1-2,N0,M0,PSA ≥20, grade group 1--4\
                                                                                                         IIIB: T3-4, N0, M0, Any PSA, grade 1--4\
                                                                                                         IIIC: Any T, N0,M0, Any PSA, grade group 5

  IV      T4 or N1 or M1         T4 N0 M0, Any PSA, Any Gleason\                                         IVA: Any T, N1, M0, Any PSA, Any grade group\
                                 N1, Any PSA, Any Gleason\                                               IVB: Any T, N0, M1, Any PSA, Any grade group
                                 M1, Any PSA, Any Gleason                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------

\*PSA laboratory examination unit was ng/ml.

External validation of the prognostic significance of these changes among different population-based databases and comparing new vs. older AJCC editions would confirm its prognostic impact; moreover, it may point out potential gaps whereby further improvements in the staging system are needed. Surveillance, epidemiology and end results (SEER) database is a valid choice for this external validation as well as for exploration of future refinements given its broad coverage and rigorous quality assurance \[[@pone.0188450.ref009]\].

Given the presence of two versions of AJCC staging system for prostate cancer based on the method of staging (i.e. clinical versus pathological staging), the current analysis is restricted to clinically staged patients in order to ensure homogeneity of the patient population.

2. Objective {#sec006}
============

The objective is to validate the prognostic value of the changes put forward in the 8^th^ edition of the AJCC staging system in a cohort of patients with clinically staged prostate cancer registered within the SEER database.

3. Methodology {#sec007}
==============

The records of this study were extracted from the SEER-18 registry \[[@pone.0188450.ref010]\]; in order to accomplish this, SEER\*Stat software Version 8.3.4 was employed.

a. Selection of the study cohort {#sec008}
--------------------------------

The SEER database search was limited to the period from 2004--2014 (because reliable PSA data were not available before that date).To identify eligible records, the ICD-O-3/WHO 2008 category of "prostate" was selected. In order to restrict the inclusion to clinically staged patients, cases with any form of radical surgical treatment to the prostate were excluded. Cases with incomplete information about survival, TNM 6^th^ stage, PSA or Gleason grade/grade group were excluded.

b. Data collection {#sec009}
------------------

Data extracted for each record included age at diagnosis, race, T, N and M stages (according to the 6^th^ edition), 6^th^ edition stage group, PSA, Gleason grade, site of distant metastatic disease (if applicable), cause-specific death classification and survival months.7^th^ and 8^th^ edition stage groups were then reconstructed for each patient according to PSA, Gleason grade/grade group and 6^th^ edition T/ N/ M stages. Through tumor extension information from the collaborative staging section, disease with microscopic bladder neck invasion (categorized as T4 in the 6^th^ edition) was down-staged to T3a (as in 7^th^ and 8^th^ editions). Grade groups were calculated based on the available Gleason scores as follows: group 1: Gleason score ≤6; group 2: Gleason score 3+4; group 3: Gleason score 4+3; group 4: Gleason score 8; group 5: Gleason score 9--10 \[[@pone.0188450.ref011]\].

In the current study, cancer-specific survival was defined as time from diagnosis to death from prostate cancer. Available SEER data about systemic as well as radiation therapy were limited by incompleteness and uncertainty (data were available as yes or no/unknown); thus, they were not included into the current analysis. Data about performance status of the patients as well as co-morbidity were not recorded in the SEER database.

c. Statistical considerations {#sec010}
-----------------------------

In this analysis, Kaplan-Meier analysis as well as log-rank testing was used for survival comparisons (both cancer-specific and overall survival) according to 6^th^, 7^th^ and 8^th^ editions of the AJCC. Regarding cancer-specific survival, cases that were alive at the end of the study as well as cases who died of causes other than cancer were censored. Median follow up for the whole cohort is 26 months.Post hoc Bonferroni correction for multiple survival comparisons was not implemented to avoid the risk of exaggerating a type II error (in the presence of numerous pair wise comparisons).Cox proportional hazard model was utilized to conduct multivariate analyses; and hazard ratios (with corresponding 95% CI) were produced for factors affecting cancer-specific and overall survival for the subgroup of patients with clinically localized disease as well as the subgroup of patients with advanced disease.Verification of the proportional hazard assumption was made though graphical assessment of the hazard plots. A result would be considered statistically significant if a two-tailed P value was \< 0.05. Moreover, a concordance index (c-index) using both death from prostate cancer and death from any cause as the dependent variables was evaluated for each of the three AJCC editions (6^th^, 7^th^ and 8^th^). C-index was calculated through binary logistic regression followed by area under the receiver operating characteristics curve were calculated. Its value gives additional insight into the discriminatory ability of each of the AJCC staging system editions. C-index was calculated for both death from prostate cancer and death from any cause in order to give extra insight about cancer-specific survival as well as overall survival. An additional modification to the sub-staging of clinically localized disease (stage I, II, III) as well as advanced disease (stage IV) was also proposed and evaluated in this study. All of the analyses were performed through SPSS Statistics 20.0 (IBM, NY).

4. Results {#sec011}
==========

a. Patients, characteristics {#sec012}
----------------------------

"[Fig 1](#pone.0188450.g001){ref-type="fig"}" details the selection process of eligible patients into this study. A total of 110499 eligible patients with prostate cancer were finally identified in the period from 2004--2014 and were included into the analysis. All patients have complete information about TNM 6^th^ edition, PSA level as well as Gleason grade/grade group. Adenocarcinoma, NOS (not otherwise specified) represents the majority of cases (99.5%), other variants represent 0.5%.Age group \< 70 years was 59.5%; while age group ≥70 years was 40.5%.[Table 2](#pone.0188450.t002){ref-type="table"} summarizes all clinicopathological characteristics of the included cohort. Distribution of the patients according to AJCC 6^th^, 7^th^ and 8^th^ editions was also reported. Moreover, classification of patients according to M stage were also reported (M0, M1a (non regional lymph nodes), M1b (bone metastases), M1c (other sites of metastases).Neither radiotherapy nor systemic therapy was reliably reported in the SEER database to be included in the analysis. All included patients did not undergo any form of radical surgery to the prostate. Median follow-up was 26 months(ranges from 1--131 months).

![Flowchart showing the selection process of eligible patients into the current study.](pone.0188450.g001){#pone.0188450.g001}

10.1371/journal.pone.0188450.t002

###### Baseline characteristics of included patients in the study (110449 patients)[\*\*](#t002fn002){ref-type="table-fn"}.

![](pone.0188450.t002){#pone.0188450.t002g}

  Parameter                                                              Number (%)
  ---------------------------------------------------------------------- ----------------
  Age                                                                    
  \<70 years                                                             65794 (59.5%)
  ≥ 70 years                                                             44655 (40.5%)
  Race                                                                   
      White                                                              81878 (74.1%)
      Black                                                              20078 (18.2%)
      Others                                                             5701 (5.2%)
      Unknown                                                            2792 (2.5%)
  Grade group                                                            51231 (46.4%)
      1                                                                  24775 (22.4%)
      2                                                                  12058 (10.9%)
      3                                                                  11556 (10.5%)
      45                                                                 10829 (9.8%)
  PSA                                                                    
  \<10                                                                   78572 (71.1%)
  ≥10- \<20                                                              17520 (15.9%)
  ≥20                                                                    14357 (13%)
  Histological subtypes                                                  
      Adenocarcinoma, NOS                                                109875 (99.5%)
      Other variants                                                     574 (0.5%)
  AJCC stage groups 6^th^ edition[\*](#t002fn001){ref-type="table-fn"}   
      I                                                                  346 (0.3%)
      II                                                                 100774 (91.2%)
      III                                                                2452 (2.2%)
      IV                                                                 6877 (6.2%)
  AJCC stage groups 7^th^ edition[\*](#t002fn001){ref-type="table-fn"}   
      I                                                                  42528 (38.5%)
      IIA                                                                36986 (33.5%)
      IIB                                                                21606 (19.6%)
      III                                                                2504 (2.3%)
      IV                                                                 6825 (6.1%)
  AJCC stage groups 8^th^ edition[\*](#t002fn001){ref-type="table-fn"}   
      I                                                                  42528 (38.5%)
      IIA                                                                6817(6.2%)
      IIB                                                                22270 (20.2%)
      IIC                                                                16895 (15.3%)
      IIIA                                                               6605 (6%)
      IIIB                                                               1739 (1.6%)
      IIIC                                                               7165 (6.5%)
      IVA                                                                1197 (1.1%)
      IVB                                                                5233 (4.7%)
  M stage                                                                
      M0                                                                 105216 (95.3%)
      M1a (non regional lymph nodes)                                     362 (0.3%)
      M1b (bone)                                                         4051 (3.7%)
      M1c (other sites)                                                  820 (0.7%)

\*AJCC: American Joint Committee on Cancer

\*\*PSA laboratory examination unit was ng/ml.

b. Survival outcomes {#sec013}
--------------------

Cancer-specific and overall survivals were compared according to AJCC 6^th^, 7^th^ and 8^th^ staging systems. Pair wise comparison between all different stages with log rank testing was conducted. For cancer- specific survival according to 8^th^ AJCC, all pair wise P values for comparison were significant (\<0.01) except for stage IIA vs. IIB; while for overall survival according to 8^th^ AJCC, all pair wise P values for comparison were significant (\<0.02) except for stage IIIA vs. IIIB "[Fig 2A and 2B](#pone.0188450.g002){ref-type="fig"}". For cancer-specific survival according to 7^th^ AJCC, all pair wise P values for comparison were significant (\<0.001); while for overall survival according to 7^th^ AJCC, all pair wise P values for comparison were significant (\<0.01) except for stage IIB vs. III "[Fig 2C and 2D](#pone.0188450.g002){ref-type="fig"}". For cancer-specific survival according to 6^th^ AJCC, all pair wise P values for comparison were significant (\<0.05) except for stage I vs. stage II; while for overall survival according to 6^th^ AJCC, all pair wise P values for comparison were significant (\<0.05) except for stage I vs. III "[Fig 2C and 2D](#pone.0188450.g002){ref-type="fig"}" (notably in overall survival assessment according to 6^th^ AJCC, stage I has worse overall survival compared to stage II).

![Kaplan--Meier curve of: a) cancer-specific survival according to the 8^th^ edition; b) overall survival according to the 8^th^ edition; c) cancer-specific survival according to the 7^th^ edition; d) overall survival according to the 7^th^ edition; e) cancer-specific survival according to the 6^th^ edition; f) overall survival according to the 6^th^ edition.](pone.0188450.g002){#pone.0188450.g002}

Results of c-index assessment for cancer-specific survival for the three editions were as follows: c-index for AJCC 6^th^ edition was 0.816; c-index for AJCC 7^th^ edition was 0.897; c-index for AJCC 8^th^ edition was 0.907. On the other hand, results of c-index assessment for overall survival for the three editions were as follows: c-index for AJCC 6^th^ edition was 0.627; c-index for AJCC 7^th^ edition was 0.704; c-index for AJCC 8^th^ edition was 0.710.

c. Proposed modifications to the AJCC 8^th^ edition {#sec014}
---------------------------------------------------

Based on the results above, two sets of modifications to the AJCC 8^th^ edition were formulated and proposed. For clinically localized disease (i.e. T any, N0, M0), three risk groups were proposed corresponding to stage I, stage II (IIA/IIB/IIC) and stage III (IIIA/IIIB/IIIC). Pair wise comparison between all different stages with log rank testing was conducted for both cancer-specific and overall survival. For both cancer-specific and overall survival, all pair wise P values for comparisons were \<0.0001 "[Fig 3A and 3B](#pone.0188450.g003){ref-type="fig"}".

![Kaplan--Meier curve of: a) cancer-specific survival according to the three risk groups for clinically localized disease; b) overall survival according to the three risk groups for clinically localized disease; c) cancer-specific survival according to the proposed sub-divisions of stage IV disease; d) overall survival according to the proposed sub-divisions of stage IV disease.](pone.0188450.g003){#pone.0188450.g003}

Moreover, all P values for pair wise comparisons in a multivariate model of factors affecting cancer-specific and overall survival (adjusted for age, race, marital status and year of diagnosis) were also significant (P\<0.0001) ([Table 3](#pone.0188450.t003){ref-type="table"}).

10.1371/journal.pone.0188450.t003

###### A multivariate Cox proportional model adjusted for age, race, year of diagnosis and marital status showing pair wise comparisons between the three stages of clinically localized disease (stage I,II,III)(AJCC 8^th^).

![](pone.0188450.t003){#pone.0188450.t003g}

  Comparison               Cancer-specific survival   Overall survival                          
  ------------------------ -------------------------- ------------------ ---------------------- ----------
  Stage II vs. stage I     2.945 (2.313--3.750)       \<0.0001           1.582 (1.485--1.684)   \<0.0001
  Stage I vs. stage III    0.044 (0.035--0.055)       \<0.0001           0.293 (0.274--0.314)   \<0.0001
  Stage II vs. stage III   0.130 (0.113--0.150)       \<0.0001           0.464 (0.438--0.492)   \<0.0001

For advanced prostate cancer (N1 orM1 disease), further sub-staging was proposed according to M1 sub-stage (i.e.N1, M1a, M1b and M1c). Pair wise comparison between these new sub-stages with log rank testing was conducted for both cancer-specific and overall survival. For both cancer-specific and overall survival, all pair wise P values for comparisons were \<0.0001 "[Fig 3C and 3D](#pone.0188450.g003){ref-type="fig"}". Moreover, all P values for pair wise comparisons in a multivariate model of factors affecting cancer-specific and overall survival (adjusted for age, race, grade group, baseline PSA level, marital status and year of diagnosis) were also significant (P\<0.0001) ([Table 4](#pone.0188450.t004){ref-type="table"}). Additionally, [Table 5](#pone.0188450.t005){ref-type="table"} summarized five year cancer-specific survival rates according to the proposed sub-stages for advanced disease.

10.1371/journal.pone.0188450.t004

###### A multivariate Cox proportional model adjusted for age, race, and year of diagnosis, marital status, grade group and baseline PSA showing pair wise comparisons between sub-stages of stage IV disease (AJCC 8^th^).

![](pone.0188450.t004){#pone.0188450.t004g}

  Comparison                      Cancer-specific survival   Overall survival                          
  ------------------------------- -------------------------- ------------------ ---------------------- ----------
  Stage IVA vs. stage IVBM1a      0.491 (0.369--0.653)       \<0.0001           0.606 (0.478--0.769)   \<0.0001
  Stage IVBM1a vs. stage IVBM1b   0.603 (0.479--0.760)       \<0.0001           0.633 (0.518--0.714)   \<0.0001
  Stage IVBM1b vs. stage IVBM1c   0.682 (0.603--0.772)       \<0.0001           0.690 (0.619--0.769)   \<0.0001

10.1371/journal.pone.0188450.t005

###### Five year cancer-specific survival rates among patients with stage IV disease (AJCC 8^th^).

![](pone.0188450.t005){#pone.0188450.t005g}

  Stage      Five year CSS rate[\*](#t005fn001){ref-type="table-fn"}   SE[\*](#t005fn001){ref-type="table-fn"}
  ---------- --------------------------------------------------------- -----------------------------------------
  IVA        72%                                                       0.03
  IVB(M1a)   54%                                                       0.05
  IVB(M1b)   43%                                                       0.02
  IVB(M1c)   30%                                                       0.03

\*CSS: cancer-specific survival; SE: standard error.

5. Discussion {#sec015}
=============

The current study provided an external validation to the prognostic performance of the AJCC 8^th^ staging system for prostate cancer. Compared to older staging systems (6^th^ and 7^th^), the 8^th^ system is more discriminatoryand the new sub-stages introduced within the 8^th^ system are prognostically relevant. Additionally, stages I, II and III in the 8^th^system correspond to three distinct risk groups in the clinically localized setting. Moreover, new sub-stages should be introduced based on the site and extent of metastatic disease in the advanced setting.

Numerous prognostic tools have been proposed for prostate cancer both in the clinically localized as well as advanced settings. These models were evaluated by the committee of the precision medicine core of the AJCC \[[@pone.0188450.ref012], [@pone.0188450.ref013]\]. However, none of the models evaluating clinically localized disease were endorsed by the AJCC because of a reported lack of validation of survival impact. The current SEER analysis provided a survival validation for a three-risk groups system in the localized setting based on the 8^th^ AJCC system. Moreover, only two of the models in advanced disease were endorsed by the AJCC \[[@pone.0188450.ref014], [@pone.0188450.ref015]\]. These models deal with castrate-resistant prostate cancer rather than treatment-naïve disease.

P values for pair wise comparisons between different stages were not consistently significant between cancer-specific and overall survival. This may be ascribed to unknown differences in baseline co-morbidities which may have contributed to an imbalance of non cancer-related deaths and hence inconsistent P value for both endpoints.

Major limitations of this analysis include: 1) No sufficiently reliable information about both systemic and radiation treatments in the SEER database. The absence of sufficient treatment details calls for extra caution when dealing with the results of this analysis particularly with regards to the proposals for combining stages IIA/IIB/IIC or stages IIIA/IIB/IIC. Some of the observed overlaps among these sub-stages may be related to unknown treatment differences rather than inherent biological similarity.2) No information about performance status and co-morbidities of the included patients; accordingly, the analysis has been based on cancer-specific in addition to overall survival in order to avoid the potential confounding effect resulting from unknown associated co-morbidities.

Following the publication of the 7^th^ edition of TNM staging system for prostate cancer, a number of validation studies have been published and they showed an evidence of improvement for the 7^th^ system compared to the 6^th^ system \[[@pone.0188450.ref016], [@pone.0188450.ref017]\].

The 8^th^ edition of the AJCC staging system places more emphasis on the histological grade as a determinant factor in the stage grouping. The more enhanced role of disease biology in the staging is based on numerous analyses which point out the pivotal role of disease biology in determining prostate cancer outcomes \[[@pone.0188450.ref018], [@pone.0188450.ref019]\].

Current study shows that c-index for AJCC 8^th^ staging system is better than that of AJCC 7^th^ and 6^th^ staging systems. This indicates the improvement of discriminatory performance of the 8^th^ staging system compared to previous systems; and indicates also that with proper integration of biological information, the prognostication of many solid tumor patients may improve.

Current analysis reveals the heterogeneity in prognosis of patients with stage IV disease. This is in line with previous population-based studies \[[@pone.0188450.ref020], [@pone.0188450.ref021]\]. Although the traditional TNM staging classifies M1 disease into three sub-stages (M1a: non regional lymph nodes; M1b: bone metastases; M1c: other sites), the AJCC stage grouping did not sub-stage metastatic patients based on these M1 sub-stages despite evidence of survival differences based on the site and pattern of distant metastases \[[@pone.0188450.ref022]\]. The current study provided additional evidence on the importance of the site of metastases on survival and called for sub-classification of stage IV patients according to the site/extent of metastases.

Given the evidence of impact of tumor grade and PSA level on the outcomes of advanced disease, further refinements in the sub-classification of advanced disease may also be achieved by incorporating grade group and PSA levels into the staging of advanced disease (just like it was incorporated into the staging of clinically localized disease) \[[@pone.0188450.ref005]\]. This is best exemplified by the recently published prostascore model which incorporated anatomical extent of the metastases, baseline PSA and grade group into a simplified prognostic model for treatment-naïve advanced prostate cancer \[[@pone.0188450.ref023]\].

In conclusion,compared to older staging systems (6^th^ and 7^th^), the 8^th^ system is more discriminatoryand the new sub-stages introduced within the 8^th^ system are prognostically relevant.
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